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Available online 21 September 2015AbstractObjective: The aim of this study is to see whether it is effective for human immunodeficiency virus (HIV) infected patients conducted partial
splenic embolization (PSE) and if there are differences in the effects of PSE between HIV and non-HIV patients.
Method: We retrospectively reviewed seven patients, three were HIV infected, the rest weren't. We compared the effects of PSE between the two
groups using indices of hematologic indices and liver function.
Result: In HIV infected patients, WBC rose in all PSE procedure, RBC rose in 3 procedures. PLT increased in 2 procedures. ALT decreased in all
patients, but the changes of ALB and AST were not obvious. In non-HIV infected patients, all the hematologic indices were increased, except
one patient. ALT and AST were increased, the change of ALB was not obvious.
Conclusion: PSE do improve the hematologic indices and liver function in patients with HIV and hepatitis virus co-infected, but when compare
with non-HIV infected patients included in our study, we haven't seen much differences in the effects.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Beijing You’an Hospital affiliated to Capital Medical University. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The co-infection of human immunodeficiency virus (HIV)
and hepatitis virus became more prevalent, because of the same
route of transmission: blood.What is worse, infection with HIV
accelerates the progression of HBV/HCVdisease to cirrhosis by
increasing hepatitis B/C viremia [1]. A study showed that non-
AIDS related death was mostly caused by liver diseases and
there was a strong relation between immunodeficiency and risk
of liver related death [2]. This means that HIV and HBV/HCV
co-infected patients may experience a higher risk of death than
other HIVor HBV/HCV infected patients. In hepatic cirrhosis,
hypohepatia, thrombocytopenia, anemia and leucopenia are
frequently occurring clinic features. Additionally,* Corresponding author. Tel.: þ86 027 67813017.
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reduction of hematologic indices [3]. Thrombocytopenia in-
creases a patient's risk of spontaneous bleeding, and may pre-
clude surgical or endovascular interventions. Leukopenia
decreases the patient's ability to overcome infection, and may
serve as a contraindication to the use of chemotherapies. Ane-
mia places a patient at a high risk of bleeding [4].
Splenectomy is a traditional treatment of hepatic cirrhosis and
hypersplenism, but it is associated with severe complications,
such as hemorrhage, thromboembolic, subphrenic abscess,
overwhelming postsplenectomy infection (OPSI) [5]. While for
partial splenic embolization (PSE), postembolization syndrome
including abdominal pain, fever, malaise, and gastrointestinal
symptoms is the most common side effect of PSE [6]. A retro-
spective study shows that both splenectomy and PSE can
improve hematologic indices, but the patients conducted sple-
netomymay experiencemore severe complications [7]. The PSE
not only improve liver function and serum cell counts, but also
decrease the incidence of variceal bleeding and the protectionof Beijing You’an Hospital affiliated to Capital Medical University. This is an
licenses/by-nc-nd/4.0/).
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hypersplenism secondary to cirrhosis and infected with HIV
virus at the same time, the effect of PSE is unclear.
2. Materials and methods2.1. MaterialsWe retrospectively analysed seven patients with liver
cirrhosis who underwent 8 PSE during 2007e2013 in Zhon-
gnan Hospital of Wuhan University. One of the patients con-
ducted twice PSE because of a smaller infarction area in the
first time. The patients included in this study were those who
conducted CT before and after PSE, and their CT images
could be seen in the PACS system in our hospital and the
WBC, RBC, PLT and liver function should be tested before
and after PSE. The patients who only conducted B ultrasound
or who hadn't had all of the biochemical tests were excluded.
The seven patients are divided into 2 groups. There are three
patients infected with HIV virus in group A, including 2
women aged 44 and 45 and a 55-year-old man. The 44 year-
old woman has had hepatitis B for more than 8 years; the
45 year-old woman was the one who received PSE twice, had
hepatitis B and C, and cirrhosis; and the man was diagnosed
with hepatitis C and cirrhosis. The remaining four patients
haven't infected with HIV virus are in group B. There are 2
women aged 56, 72 and 2 men aged 53, 54. Both group pa-
tients have bad liver functions and splenomegaly confirmed by
computered tomography, and associated decreasing hemato-
logic indices including thrombocytopenia and leucopenia.2.2. MethodsWe used Seldinger's method through the right femoral ar-
tery puncture. Via a 5 F arterial sheath pipe, we inserted thePicture 1. The digital subtraction angiography (DSA) pictures of a 46 years old wo
splenic artery is wide and has many branches. B: digital subtraction splenic arteriog
terminal arteries of spleen are embolized.catheter into proximal splenic artery and conducted angiog-
raphy to map the distribution and branches of the splenic ar-
tery, and the size of spleen. Then we further advanced the
catheter to reach to the distal splenic artery or the hilum of
spleen. Amount of gelatin sponge needed is based on the
number of splenic artery branches with a diameter of 1 mm.
Also, we needed to treat patients accordingly based on their
conditions to control the embolism area within 30%e70%.
The procedure was performed under X-ray fluoroscopy. We
used low-pressure flow control technology to inject gelfoam.
All the gelfoam were produced by HangZhou Alicon Pharma
Science and technology Company and the size of gelfoam
were 500e1000um. We judged embolism area according to
blood flow speed and contrast reflux (Picture 1). After oper-
ation, the patients should lie in bed and apply local
compression for 24 h. Antibiotics may be required if embolism
syndrome such as fever, spleen pain, nausea and other symp-
toms appear.2.3. Observation itemsWe observed and recorded the indices of liver function
including alanine aminotransferase (ALT), aspartate amino-
transferas(AST), albumin(ALB), the size of spleen and he-
matologic indices including thrombocyte, leukocyte and
erythrocyte counts before and after PSE.
3. Result
PSE were conducted successfully in both groups. In group
A, 1 of 4 patients experienced transient abdominal tenderness
and disappeared 4 days later without any treatment; 1 of 4
patients developed abdominal pain during the night following
the procedure and were given painkillers. The last patient
received PSE twice and during the first time, the patient had noman with HIV and cirrhosis. A: pre-embolization arteriogram shows the main
ram obtained after embolization of approximately 50% of the spleen shows the
Picture 2. The CT images of the same HIV infected patient. A, B: before embolization, the spleen is much bigger than ordinary. C, D: after embolization, the
volume of spleen is reduced, we can see the embolization part in picture C with lower density than the normal part.
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ever, after the second PSE, the patient had transient abdominal
pain, fever, and vomit and recovered gradually with symp-
tomatic treatment. In group B, all of the 4 patients got
abdominal pain and 2 of 4 had fever after PSE and received
symptomatic treatment. None of the patients got severe post-
embolization complications such as splenic abscess, splenic
rupture, and refractory ascite and so on.
On the basis of the CT findings after embolization, the
splenic infarction percentages in group A were 50% in 2 of 4
and 35%, 45% in the patient who received PSE twice. In group
B, the embolization area is 40%e70% (Picture 2). Changes ofTable 1
Characteristics of hematologic indices and liver functional parameters of group A
Patients Items
PLT (1  109 g/l) WBC (1  109 g/l) RB
1 44 1.51 2.32
30 7.52 2.58
2 34 1.13 3.13
42 7.90 3.23
2* 39 1.36 2.97
44 1.56 2.64
3 61 2.30 3.59
52 4.80 3.93
Note: the data before PSE is shown upper the data after PSE. 2* means the patienblood cell counts, and liver function, in both group A and
group B prior to procedures and 1 week after the procedures,
are shown in Tables 1 and 2, respectively. In group A, the
white cell rose differently after the embolization in all pa-
tients. One of 4 patients showed little decline in RBC, while 3
of 4 patients showed increases in RBC. But the platelet counts
didn't show significant increase in all patients after PSE, with 2
of 4 rose slightly and the others decreased. The decrease of
ALT, which is an indicator of recovery of hepatic function, is
observed in all patients. But the changes in ALB and AST
were not obvious, with 2 of 4 declined, 1 of 4 increased
slightly, and 1 of 4 with no change. In group B, all thebefore and one week after PSE.
C (1  109 g/l) ALT (u/l) AST (u/l) ALB (g/l)
14 24 37.3
10 44 38.8
43 44 27.3
35 41 29.3
40 41 27.7
24 41 27.1
28 40 36.5
22 44 34.9
t receive second time PSE.
Table 2
Characteristics of hematologic indices and liver functional parameters of group B before and one week after PSE.
Patients Items
PLT (1  109 g/l) WBC (1  109 g/l) RBC (1  109 g/l) ALT (u/l) AST (u/l) ALB (g/l)
1 58 1.56 3.62 110 93 37.0
92 3.74 3.73 54 42 36.0
2 62 3.82 3.37 55 62 30.8
125 9.23 3.31 33 47 37.3
3 53 2.59 3.53 48 44 33.4
100 7.24 3.76 29 32 29.7
4 39 2.0 3.41 37 50 31.9
66 5.3 2.76 16 28 24.9
Note: the data before PSE is shown upper the data after PSE.
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declined in RBC. ALT and AST decreased in all patients.
While the change of ALB was not obvious, 1 of 4 increased a
little and 3 of 4 decreased. In general, all patients had smaller
splenic volume after the procedure, WBC and RBC were
increased in both groups but the improvements were not
significantly different. The outcome of PLT in group B was
better than in group A.
4. Discussion
Thomas et al. [9] indicates that both PSE and splenetomy
can improve PLT and WBC counts so as to allow for use of
drugs, which suppress the bone marrow such as interferon or
chemotherapeutic agents, to successfully treat the infection.
The condition is also suitable for HIV-HBV/HCV co-infected
patients, for whom highly active antiretroviral therapy is also
needed to be used to improved prognosis of HIV infection and
reduced the incidence of opportunistic diseases substantially
[10]. Dua RS et al. retrospectively analysed 477 HIV infected
patients who received 722 surgical procedures found that a
significantly higher risk of complication followed intra-
abdominal procedures, the septic sequelae (pelvic collections
and wound infections) were the most common complications
which were all related to delayed healing of wounds [11].
Compared with splenetomy, PSE is much safer which causes
less severe complications and shorter length of stay in hospital
[7].
Research indicates that end-stage liver disease, which may
lead to spontaneous bacterial peritonitis, hepatic encephalop-
athy, or gastrointestinal bleeding secondary to esophageal
varices or coagulopathy, has become the leading cause of
death in HIV infected patients [12]. So improving the hepatic
function is of vital importance in HIV and HBV/HCV co-
infected patients. Moreno et al. indicated that PSE, with a
mean infracted area of 80%, conducted in HIV and HCV co-
infected patients, leading to a significant increase in platelet
and leukocyte counts [13]. In our study, the leukocyte counts
increased in all patients, but the platelet counts only increased
in 2 of 4, which is consistent with Moreno's research at some
degree. Additionally, all patients in group A have a decrease in
ALT, showing recovery of liver function, but 2 of 4 had an
increase in AST and ALB. Unfortunately, there is no research
about the changes of liver function after received PSE in HIVinfected patients. In group B, the results of PLT, WBC, RBC
and ALT, AST are compatible with previous research [7], with
all the hematologic indices were significantly increased,
except one declined in RBC; ALT and AST decreased in all
patients. Hiromitsu Hayashi et al. [14] also suggested that
preoperative splenic volume and infarcted splenic volume
were positively associated with liver functional improvement.
Maybe this is the reason why the results of liver functional
improvements in group A, which have a smaller infarcted
splenic volume, are not as good as in group B.
The most common complication of post PSE is post
embolization syndrome, including fever, abdominal pain,
needing only symptomatic treatment. Some severe side effects
such as splenic abscess and splenic rupture haven't appeared in
our study. Hayashi et al. indicates that a massive infarcted
splenic volume, not splenic infarction rate, is correlated with
complications after PSE for liver cirrhosis and an infarcted
splenic volume of between 388 and 540 ML is recommended
for safe and effective PSE in patients with cirrhosis [15]. Other
study indicates that the rate of splenic infarction is a critical
factor for long-term improvement of blood cell counts and the
splenic infarction rate should be limited to 50%e70% in order
to ensure the long-term efficacy in alleviating hypersplenism
and reducing complications [16].
Our study do had some limitations. First, our sample size is
too small that many biases may exist in our results. Second,
the patients in our study had a short following up time. Third,
there is litter article about the accurate effects of PSE in HIV
infected patients, so we cannot make a comparison with other
researches. Therefore, we should accept the results cautiously
and much more studies need to be done in this aspect to know
the accurate effects of PSE in HIV infected patients.
5. Conclusion
Based on the patients included in our study, PSE do
improve the PLT or RBC or WBC or PLT in HIV infected
patients and without severe side effects, which means that PSE
is an effective way to relieve hypersplenism and improve liver
fuction. And when compared with the non-HIV infected pa-
tients included in our study, we haven't seen much difference
of the effects of PSE. What is more, considering the limita-
tions in this study, we should accept the results cautiously, and
more works should be done in this aspect.
76 H. Zhang et al. / Radiology of Infectious Diseases 2 (2015) 72e76References
[1] Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, García-
Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency
virus infection modifies the natural history of chronic parenterally-
acquired hepatitis C with an unusually rapid progression to cirrhosis. J
Hepatol 1997;26:1e5.
[2] Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al.
Liver-related deaths in persons infected with the human immunodefi-
ciency virus: the D: A:D study. Arch Intern Med 2006;166:1632e41.
[3] Marks PW. Hematologic manifestations of liver disease. Semin Hematol
2013;50:216e21.
[4] Hadduck TA, McWilliams JP. Partial splenic artery embolization in
cirrhotic patients. World J Radiol 2014;6:160e8.
[5] Weledji EP. Benefits and risks of splenectomy. Int J Surg 2014;12:113e9.
[6] Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA.
Partial splenic embolization versus splenectomy for the management of
hypersplenism in cirrhotic patients. World J Surg 2009;33:1702e10.
[7] Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T.
Long-term hematological and biochemical effects of partial
splenic embolization in hepatic cirrhosis. Hepatogastroenterology
2002;49(47):1445e8.
[8] Smith M, Ray CE. Splenic artery embolization as an adjunctive proce-
dure for portal hypertension. Semin Interv Radiol 2012;29:135e9.[9] Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it?
Liver Int 2015;35:1492e8.
[10] Spengler U. Management of end-stage liver disease in HIV/hepatitis C
virus co-infection. Curr Opin HIV AIDS 2011;6:527e33.
[11] Dua RS, Wajed SA, Winslet MC. Impact of HIV and AIDS on surgical
practice. Ann R Coll Surg Engl 2007;89:354e8.
[12] Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T,
et al. Predictive factors for platelet increase after partial splenic embo-
lization in liver cirrhosis patients. J Gastroenterol Hepatol
2007;22:1638e42.
[13] Moreno A, Barcena R, Blazquez J, Quereda C, Gil-Grande L, Sanchez J,
et al. Partial splenic embolization for the treatment of hypersplenism in
cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin.
Antivir Ther 2004;9:1027e30.
[14] Hayashi H, Beppu T, Masuda T, Okabe H, Imai K, Hashimoto D, et al.
Large splenic volume may be a useful predictor for partial splenic
embolization-induced liver functional improvement in cirrhotic patients.
J Hepatobiliary Pancreat Sci 2014;21:51e7.
[15] Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors
for complications after partial splenic embolization for liver cirrhosis. Br
J Surg 2008;95:744e50.
[16] Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, et al. Partial splenic
embolization for hypersplenism in cirrhosis: a long-term outcome in 62
patients. Dig Liver Dis 2009;41:411e6.
